Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Plectasin NZ2114 – Novel Microbial Agent

Novozymes A/S and Sanofi-Aventis have signed a global licensing agreement for further development and marketing of plectasin NZ2114.

  • Plectasin NZ2114 antimicrobial peptide
  • Antibiotic resistance
  • Plectasin NZ2114 further development

Go Top